Ocular Therapeutix/$OCUL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocular Therapeutix
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Ticker
$OCUL
Sector
Primary listing
Employees
274
Headquarters
Website
OCUL Metrics
BasicAdvanced
$2.6B
-
-$1.28
1.49
-
Price and volume
Market cap
$2.6B
Beta
1.49
52-week high
$13.85
52-week low
$5.79
Average daily volume
3.4M
Financial strength
Current ratio
10.095
Quick ratio
9.827
Long term debt to equity
24.292
Total debt to equity
25.15
Interest coverage (TTM)
-19.56%
Profitability
EBITDA (TTM)
-237.316
Gross margin (TTM)
-214.09%
Net profit margin (TTM)
-382.51%
Operating margin (TTM)
-425.73%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-31.14%
Return on equity (TTM)
-63.41%
Valuation
Price to revenue (TTM)
36.452
Price to book
6.9
Price to tangible book (TTM)
6.9
Price to free cash flow (TTM)
-11.516
Free cash flow yield (TTM)
-8.68%
Free cash flow per share (TTM)
-1.059
Growth
Revenue change (TTM)
-7.26%
Earnings per share change (TTM)
2.35%
3-year revenue growth (CAGR)
4.32%
10-year revenue growth (CAGR)
43.48%
3-year earnings per share growth (CAGR)
8.22%
10-year earnings per share growth (CAGR)
-2.43%
What the Analysts think about OCUL
Analyst ratings (Buy, Hold, Sell) for Ocular Therapeutix stock.
Bulls say / Bears say
As of June 30, 2025, Ocular Therapeutix held $391.1 million in cash and cash equivalents, providing substantial liquidity to fund its commercial operations and advance clinical programs. (SEC Filing)
The FDA granted Special Protocol Assessment for the registrational NPDR trial of AXPAXLI, aligning study design with regulatory expectations and reducing approval risk. (GlobeNewswire)
DEXTENZA end-user unit sales rose 5% year-over-year and net product revenue climbed 26% sequentially in Q2 2025, demonstrating resilient demand despite reimbursement pressures. (GlobeNewswire)
Total net product revenue in Q2 2025 fell 18.1% to $13.4 million year-over-year, as evolving reimbursement challenges weighed on DEXTENZA sales. (SEC Filing)
Research and development expenses rose to $51.1 million in Q2 2025 from $28.9 million in Q2 2024, reflecting intensifying spend on Phase 3 trials and adding near-term cash burn pressure. (GlobeNewswire)
Key Phase 3 trial readouts for SOL-1 and SOL-R are not expected until Q1 2026 and H1 2027, making valuation highly sensitive to binary clinical outcomes. (TipRanks)
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
OCUL Financial Performance
Revenues and expenses
OCUL Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocular Therapeutix stock?
Ocular Therapeutix (OCUL) has a market cap of $2.6B as of October 18, 2025.
What is the P/E ratio for Ocular Therapeutix stock?
The price to earnings (P/E) ratio for Ocular Therapeutix (OCUL) stock is 0 as of October 18, 2025.
Does Ocular Therapeutix stock pay dividends?
No, Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders as of October 18, 2025.
When is the next Ocular Therapeutix dividend payment date?
Ocular Therapeutix (OCUL) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocular Therapeutix?
Ocular Therapeutix (OCUL) has a beta rating of 1.49. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.